EDQM Releases Document on Recombinant Viral Vectored Vaccines for COVID-19

Article

The document provides analytical strategy options for the control of recombinant viral vectored vaccines to support COVID-19 vaccine developers.

The European Directorate for the Quality of Medicines and HealthCare (EDQM) announced on Nov. 3, 2020 the release of a document that discusses the control of viral vectored vaccines. The document was created in collaboration with the European Pharmacopoeia Group of Experts on vaccines for human use to support COVID-19 vaccine developers.

The document, titled “Recombinant Viral Vectored Vaccines for Human Use”, provides analytical strategy options for the control of recombinant viral vectored vaccines and includes recommendations on tests that can be used as an aid “in building appropriate analytical strategies,” EDQM stated in a press release. Topics covered in the document include substrate for recombinant viral vector propagation, recombinant viral vector seed lot propagation and harvest, purified harvest, final bulk, and final lot.

Source: EDQM​

Recent Videos
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Positive Early Data Seen in COVID-19 Monoclonal Antibody Treatment

Susan Haigney
June 26th 2025
Article

The next-generation monoclonal antibody could potentially be used to prevent and treat active COVID-19 infections, according to its developer, providing a non-vaccine option.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

EDQM Announces Digital Version of the European Pharmacopoeia

Susan Haigney
June 26th 2025
Article

EDQM is providing the 12th edition of the European Pharmacopoeia as an all-digital, redesigned, user-friendly issue.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

EMA Conditionally Authorizes Stem Cell Therapy for Blood Cancers

Susan Haigney
June 23rd 2025
Article

The agency has recommended conditional marketing authorization for Zemcelpro (dorocubicel/unexpanded umbilical cord cells) to treat adults with hematological malignancies (blood cell cancers).

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). | Image Credit: © Tada Images - stock.adobe.com

FDA Halts Clinical Trials That Send US Patient Cells to Foreign Labs

Patrick Lavery
June 20th 2025
Article

Some of the companies that received American samples, FDA said, are partially owned or controlled by the Communist Party in China.

Bioreactor. Cultivation of microorganisms in the bioreactor. Laboratory fermenter. Microbial fermentation. The creation of drugs. Microbiology. Biotech industry. Pharmacology. | Image Credit: © Grispb - stock.adobe.com

Aragen to Commence GMP Manufacturing at India Biologics Facility in July 2025

Patrick Lavery
June 16th 2025
Article

The company’s successful completion of facility and equipment qualifications gives it another biologics manufacturing option alongside its United States campus in Morgan Hill, Calif.

Washington, DC, USA - June 24, 2022: The symbol of the U.S. Department of Health and Human Services is seen at the entrance to its headquarters in the Hubert H. Humphrey Building in Washington, DC | Image Credit: © Tada Images - stock.adobe.com.

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

Christopher Cole
June 10th 2025
Article

The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond.

© 2025 MJH Life Sciences

All rights reserved.